Table 3.
Univariate analysis of pCR and MPR for neoadjuvant chemotherapy or combined with immunotherapy group
| Characteristic | Univariate for pCR and MPR in neoadjuvant chemotherapy combined with immunotherapy group | Univariate for pCR and MPR in neoadjuvant chemotherapy group | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| p-value for pCR | Odds ratio (95% CI) | p-value for MPR | Odds ratio (95% CI) | p-value for pCR | Odds ratio (95% CI) | p-value for MPR | Odds ratio (95% CI) | |
| Sex | ||||||||
|
| ||||||||
| Male or female | 0.129 | 2.851 (0.737–11.031) | 0.102 | 3.517 (1.023–12.097) | 0.590 | - | 0.793 | 0.805 (0.160–4.046) |
|
| ||||||||
| Age (yr) | ||||||||
|
| ||||||||
| < 61 or ≥ 61 | 0.340 | 0.624 (0.237–1.643) | 0.388 | 0.534 (0.922–5.930) | 0.973 | 0.976 (0.228–4.171) | 0.349 | 0.563 (0.169–1.876) |
|
| ||||||||
| Smoking history (smoker, ex-smoker or never smoker) | 0.695 | 1.265 (0.391–4.096) | 0.138 | 2.420 (0.753–7.774) | 0.860 | 1.217 (0.137–10.803) | 0.456 | 2.250 (0.267–18.955) |
|
| ||||||||
| Histology | 0.082 | 0.014 | 0.644 | 0.349 | ||||
|
| ||||||||
| Squamous cell carcinomas | 0.983 | 0.987 (0.293–3.326) | 0.897 | 0.923 (0.273–3.118) | 0.460 | 0.408 (0.038–4.395) | 0.935 | 0.909 (0.091–9.035) |
|
| ||||||||
| Adenocarcinoma | 0.068 | 4.500 (0.893–22.668) | 0.025 | 5.777 (1.241–25.878) | 0.349 | 0.286 (0.021–3.921) | 0.349 | 0.286 (0.021–3.921) |
|
| ||||||||
| Others | 1 | 1 | 1 | 1 | ||||
|
| ||||||||
| Neoadjuvant therapy number of cycles (≤ 2 or >2) | 0.187 | 0.532 (0.208–1.358) | 0.429 | 0.699 (0.288–1.696) | 0.544 | 1.673 (0.317–8.830) | 0.342 | 1.944 (0.493–7.666) |
|
| ||||||||
| N (N0 or N1–2) | 0.007 | 17.419 (2.190–138.540) | 0.001 | 9.130 (2.413–34.546) | 0.095 | 0.162 (0.019–1.374) | 0.039 | 0.192 (0.040–0.923) |
|
| ||||||||
| Baseline CEA (normal or high) | 0.033 | 3.261 (1.103–9.637) | 0.018 | 3.281 (1.231–8.745) | 0.859 | 1.146 (0.256–5.127) | 0.874 | 1.102 (0.330–3.687) |
|
| ||||||||
| Preoperative CEA (normal or high) | 0.150 | 3.266 (0.653–16.338) | 0.296 | 2.000 (0.545–7.337) | 0.657 | 0.710 (0.156–3.221) | 0.988 | 0.990 (0.275–3.561) |
|
| ||||||||
| Baseline SCC (normal or high) | 0.304 | 0.591 (0.217–1.610) | 0.164 | 0.502 (0.191–1.324) | 0.924 | 0.929 (0.207–4.173) | 0.410 | 0.607 (0.185–1.992) |
|
| ||||||||
| Preoperative SCC (normal or high) | 0.564 | 0.684 (0.189–2.478) | 0.135 | 2.640 (0.738–9.439) | 0.409 | 0.540 (0.125–2.332) | 0.643 | 0.741 (0.208–2.640) |
|
| ||||||||
| Baseline TPSA (normal or high) | 0.539 | 0.727 (0.263–2.009) | 0.964 | 0.977 (0.366–2.609) | 0.658 | 1.403 (0.314–6.260) | 0.612 | 1.366 (0.409–4.557) |
|
| ||||||||
| Preoperative TPSA (normal or high) | 0.173 | 2.631 (0.654–10.590) | 0.101 | 3.136 (0.878–10.209) | 0.628 | 1.429 (0.260–7.854) | 0.643 | 1.343 (0.386–4.668) |
|
| ||||||||
| Baseline NLR (normal or high) | 0.001 | 6.286 (2.117–18.668) | 0.005 | 4.371 (1.556–12.282) | 0.020 | 12.000 (1.498–11.28) | 0.090 | 6.000 (0.756–47.63) |
|
| ||||||||
| Preoperative NLR (normal or high) | 0.004 | 4.500 (1.614–12.549) | 0.023 | 2.931 (1.159–7.413) | 0.032 | 6.240 (1.175–33.144) | 0.039 | 3.636 (1.069–12.375) |
CEA, carcinoembryonic antigen; CI, confidence interval; MPR, major pathologic response; NLR, neutrophil-to-lymphocyte ratio; pCR, pathological complete response; SCC, squamous cell carcinoma antigen; TPSA, total prostate specific antigen.